RT Journal
A1 Wan J, Abuabara K, Troxel AB, et al
T1 DErmatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis
JF Archives of Dermatology
JO Archives of Dermatology
YR 2012
FD April 1
VO 148
IS 4
SP 539
OP 541
DO 10.1001/archdermatol.2011.1399
UL http://dx.doi.org/10.1001/archdermatol.2011.1399
AB 
Approximately 1.2 million Americans have moderate to severe psoriasis, a chronic, inflammatory disease of the skin and joints that has substantial impact on health-related quality of life and is associated with excess cardiovascular risk and mortality.1 Despite the rapid growth of treatments for psoriasis, insufficient data exist to distinguish between first- and second-line therapies. Thus, as emphasized by the Institute of Medicine,2 there exists a critical need for comparative effectiveness research (CER) in psoriasis treatment. Since a crucial component of CER is to identify the priorities of stakeholders such as physicians, we conducted a study to describe US dermatologists' preferences for which treatments to compare in future randomized controlled trials (RCTs) in moderate to severe psoriasis.